PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma

Despite increasing incidence, treatment for hepatoblastoma has not changed significantly over the past 20 years. Chemotherapeutic strategies continue to rely on cisplatin, as it remains the most active single agent against hepatoblastoma. However, chemoresistance remains a significant challenge with...

Full description

Saved in:
Bibliographic Details
Published in:Sci Rep
Main Authors: Marayati, Raoud, Stafman, Laura L., Williams, Adele P., Bownes, Laura V., Quinn, Colin H., Aye, Jamie M., Stewart, Jerry E., Yoon, Karina J., Anderson, Joshua C., Willey, Christopher D., Beierle, Elizabeth A.
Format: Artigo
Language:Inglês
Published: Nature Publishing Group UK 2021
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7966748/
https://ncbi.nlm.nih.gov/pubmed/33727604
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-85289-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items